Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical application of composition for treating atherosclerosis

A technique for atherosclerosis and composition, which is applied in the field of therapeutic use of atherosclerosis, can solve the problems of plaque fragmentation, undisclosed atherosclerotic plaque treatment methods and therapeutic effects, embolism, etc., and achieves inhibition of development, The effect of reducing the area and volume, reducing the content

Pending Publication Date: 2020-11-27
成都因诺科创生物科技有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the specific treatment methods and therapeutic effects for atheromatous plaques are not disclosed in this patent application
Moreover, this method may cause plaque fragmentation, and the fragmented part may cause serious consequences such as embolism with blood circulation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical application of composition for treating atherosclerosis
  • Pharmaceutical application of composition for treating atherosclerosis
  • Pharmaceutical application of composition for treating atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Preparation and stability test of embodiment 1 composition

[0060] Mix 5wt% human serum albumin solution (HSA) at a volume ratio of 3:1:9, copper sulfate solution (CuSO 4 ) and 5wt% glucose solution, and filled the mixed solution with about 76.077mL of perfluoropropane, then used a sonicator to vibrate the liquid-gas mixture (30% amplitude for 120 seconds, 80% amplitude for 30 seconds). That is, the composition of the present invention was prepared and stored at 4°C.

[0061] Observe the stability of the microbubble solution system during preservation at 4°C, wherein the microbubble rupture within 5 hours is extremely unstable (expressed by ××); the microbubble rupture within 12 hours is unstable (expressed by ×) Indicated by ); standing within 24 hours of microbubble rupture is stable (indicated by Δ); standing for 1 to 3 months without microbubble rupture is stable (indicated by 0); and standing for more than 3 months The microbubbles are not broken, which means th...

Embodiment 2

[0068] The preparation of embodiment 2 compositions of the present invention

[0069] Mix 5wt% human albumin solution with 1mg / mL copper sulfate solution at a ratio of 3:1, then quantitatively fill 76.077mL of perfluoropropane into the albumin-copper sulfate mixed solution, and then use an ultrasonic breaker to (20KHz) sonicate the liquid-gas mixture until the mixture becomes a light pink milky suspension. Finally, the average particle size of the microbubbles in the composition solution was detected to be about 1.05 μm, and the copper concentration was about 48.88±4.647 μg / mL. The resulting solution was stored at 4°C and used in the following examples.

[0070] Mix 5wt% human albumin solution with 5wt% glucose solution at a ratio of 3:1, then quantitatively fill 38.04 mL of perfluoropropane into the 5% albumin-5% glucose solution, and then use a sonicator ( 20KHz) to vibrate the liquid-gas mixture until the mixture becomes a white milky suspension. Finally, the average par...

Embodiment 3

[0071] The establishment of embodiment 3 rabbit atherosclerosis model

[0072] This experiment adopts the high-cholesterol diet feeding method, and the high-cholesterol feed is made by the farm of Sichuan Experimental Animal Special Committee. The specific method is as follows: adding cholesterol granules to the pulverized common feed by 1% by mass, mixing and then repressing to obtain high-cholesterol granule feed. New Zealand white rabbits are sensitive to high-cholesterol diets, and simply increasing the cholesterol in the diets can induce the formation of atherosclerotic lesions in animals, and the pathophysiological process is similar to that of humans. And without other intervention, only diet induction can better simulate human beings. Rabbit atherosclerosis models were established by feeding New Zealand white rabbits with the above-mentioned high-cholesterol diet for 12 weeks.

[0073] According to the sampling and measurement method in the following example 4, the p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
boiling pointaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses pharmaceutical application of a composition for treating atherosclerosis. The invention particularly relates to an application of a composition containing microbubbles and copper ions in preparation of a medicine for treating atherosclerosis. When the microbubble and copper ion composition disclosed by the invention is used for treating atherosclerosis, the plaque area is obviously reduced, but plaque fragmentation and shedding are not caused.

Description

technical field [0001] The present invention relates to the treatment of atherosclerosis, in particular to the application of therapeutic agents carried by microbubbles in the treatment of atherosclerosis. Background technique [0002] Healthy arteries are elastic, but over time the arterial walls can harden, a condition commonly known as atherosclerosis. The lesions of the affected arteries start from the intima, and there are local lipid accumulation, fibrous tissue hyperplasia and calcium deposition, forming plaques. Atherosclerosis is called atherosclerosis because of the yellow ather-like appearance of lipids that build up in the lining of the arteries. It is the most common disease in the cardiovascular and cerebrovascular systems, mainly affecting large and medium arteries in the body, such as coronary arteries, carotid arteries, cerebral arteries, and renal arteries. [0003] Atherosclerosis is a slowly progressive disease, which may start in childhood, with no obv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/34A61K47/64A61K9/50A61P9/10
CPCA61K33/34A61K9/5052A61P9/10A61K41/0028A61K47/42A61K9/0019A61K47/26A61K47/6925
Inventor 康裕建
Owner 成都因诺科创生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com